The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Risk of cytopenia and infection with early intervention for CRS after CAR T-cell therapy in LBCL
Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses a retrospective analysis evaluating the management of cytokine release syndrome (CRS) after CAR T-cell therapy for large B-cell lymphoma (LBCL), highlighting that early intervention for CRS at grade 1 was found to be associated with an increased risk of cytopenias and infections but did not affect the incidence of immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
